Literature DB >> 33990636

Comparison of gene expression and biotransformation activity of HepaRG cells under static and dynamic culture conditions.

Loes P M Duivenvoorde1, Jochem Louisse2, Nicole E T Pinckaers2, Tien Nguyen2, Meike van der Zande2.   

Abstract

Flow conditions have been shown to be important in improving longevity and functionality of primary hepatocytes, but the impact of flow on HepaRG cells is largely unknown. We studied the expression of genes encoding CYP enzymes and transporter proteins and CYP1 and CYP3A4 activity during 8 weeks of culture in HepaRG cells cultured under static conditions (conventional 24-/96-well plate culture with common bicarbonate/CO2 buffering) and under flow conditions in an organ-on-chip (OOC) device. Since the OOC-device is a closed system, bicarbonate/CO2 buffering was not possible, requiring application of another buffering agent, such as HEPES. In order to disentangle the effects of HEPES from the effects of flow, we also applied HEPES-supplemented medium in static cultures and studied gene expression and CYP activity. We found that cells cultured under flow conditions in the OOC-device, as well as cells cultured under static conditions with HEPES-supplemented medium, showed more stable gene expression levels. Furthermore, only cells cultured in the OOC-device showed relatively high baseline CYP1 activity, and their gene expression levels of selected CYPs and transporters were most similar to gene expression levels in human primary hepatocytes. However, there was a decrease in baseline CYP3A4 activity under flow conditions compared to HepaRG cells cultured under static conditions. Altogether, the present study shows that HepaRG cells cultured in the OOC-device were more stable than in static cultures, being a promising in vitro model to study hepatoxicity of chemicals upon chronic exposure.

Entities:  

Year:  2021        PMID: 33990636     DOI: 10.1038/s41598-021-89710-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  39 in total

1.  Interindividual variability in gene expression profiles in human hepatocytes and comparison with HepaRG cells.

Authors:  Alexandra Rogue; Carine Lambert; Catherine Spire; Nancy Claude; André Guillouzo
Journal:  Drug Metab Dispos       Date:  2011-10-12       Impact factor: 3.922

2.  Functional expression, inhibition and induction of CYP enzymes in HepaRG cells.

Authors:  Miia Turpeinen; Ari Tolonen; Christophe Chesne; André Guillouzo; Jouko Uusitalo; Olavi Pelkonen
Journal:  Toxicol In Vitro       Date:  2009-03-26       Impact factor: 3.500

3.  Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells.

Authors:  Caroline Aninat; Amélie Piton; Denise Glaise; Typhen Le Charpentier; Sophie Langouët; Fabrice Morel; Christiane Guguen-Guillouzo; André Guillouzo
Journal:  Drug Metab Dispos       Date:  2005-10-04       Impact factor: 3.922

4.  Infection of a human hepatoma cell line by hepatitis B virus.

Authors:  Philippe Gripon; Sylvie Rumin; Stephan Urban; Jacques Le Seyec; Denise Glaise; Isabelle Cannie; Claire Guyomard; Josette Lucas; Christian Trepo; Christiane Guguen-Guillouzo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-13       Impact factor: 11.205

5.  A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.

Authors:  Steven N Hart; Ye Li; Kaori Nakamoto; Eva-anne Subileau; David Steen; Xiao-bo Zhong
Journal:  Drug Metab Dispos       Date:  2010-03-12       Impact factor: 3.922

6.  Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins.

Authors:  H H J Gerets; K Tilmant; B Gerin; H Chanteux; B O Depelchin; S Dhalluin; F A Atienzar
Journal:  Cell Biol Toxicol       Date:  2012-01-19       Impact factor: 6.691

7.  Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells.

Authors:  Sébastien Anthérieu; Christophe Chesné; Ruoya Li; Sandrine Camus; Agustin Lahoz; Laura Picazo; Miia Turpeinen; Ari Tolonen; Jouko Uusitalo; Christiane Guguen-Guillouzo; André Guillouzo
Journal:  Drug Metab Dispos       Date:  2009-12-17       Impact factor: 3.922

8.  Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies.

Authors:  Kajsa P Kanebratt; Tommy B Andersson
Journal:  Drug Metab Dispos       Date:  2008-04-02       Impact factor: 3.922

9.  Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies.

Authors:  Rozenn Jossé; Caroline Aninat; Denise Glaise; Julie Dumont; Valérie Fessard; Fabrice Morel; Jean-Michel Poul; Christiane Guguen-Guillouzo; André Guillouzo
Journal:  Drug Metab Dispos       Date:  2008-03-17       Impact factor: 3.922

10.  Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor.

Authors:  Virginie Cerec; Denise Glaise; Delphine Garnier; Serban Morosan; Bruno Turlin; Bernard Drenou; Philippe Gripon; Dina Kremsdorf; Christiane Guguen-Guillouzo; Anne Corlu
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

View more
  1 in total

Review 1.  Implementing organ-on-chip in a next-generation risk assessment of chemicals: a review.

Authors:  Katharina S Nitsche; Iris Müller; Sophie Malcomber; Paul L Carmichael; Hans Bouwmeester
Journal:  Arch Toxicol       Date:  2022-02-01       Impact factor: 5.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.